Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15
Monoclonal antibody (MAb) FC-2.15 recognizes Lewis x antigen (Le(x)-Ag) expressed on the cell surface of most human breast cancer cells. FC-2.15 displays important human complement (C')-mediated cytotoxicity (CMC) against its target cells. In this study the reactivity of FC-2.15 against drug re...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
1998
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 11383caa a22011897a 4500 | ||
|---|---|---|---|
| 001 | PAPER-2989 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203228.0 | ||
| 008 | 190411s1998 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0031963756 | |
| 024 | 7 | |2 cas |a Antibodies, Monoclonal; Antigens, CD15; Antineoplastic Agents; Doxorubicin, 23214-92-8; Paclitaxel, 33069-62-4; sialosyl dimeric Le(x) antigen | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a BCTRD | ||
| 100 | 1 | |a Ballaré, C. | |
| 245 | 1 | 0 | |a Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15 |
| 260 | |c 1998 | ||
| 270 | 1 | 0 | |m Mordoh, J.; Inst. de Investigaciones Bioquimicas, 'Fundacion Campomar', Patricias Argentinas 435, 1405 Buenos Aires, Argentina; email: mordohfc@iris.iib.uba.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Mordoh, J., Leis, S., Bravo, A.I., Podhajcer, O., Ballaré, C., Capurro, M., Kairiyama, C., Bover, L., Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias (1994) Int J Biol Markers, 9, pp. 125-134 | ||
| 504 | |a Capurro, M., Bover, L., Portela, P., Livingston, P., Mordoh, J., FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis x hapten Cancer Immunol Immunother, , in press | ||
| 504 | |a Ballaré, C., Barrio, M., Portela, P., Mordoh, J., Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells (1995) Cancer Immunol Immunother, 41, pp. 15-22 | ||
| 504 | |a Mordoh, J., Silva, C., Albarellos, M., Bravo, A.I., Kairiyama, C., Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells (1995) J Immunother, 17, pp. 151-160 | ||
| 504 | |a McClean, S., Hill, B.T., An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro (1992) Biochim Biophys Acta, 1114, pp. 107-127 | ||
| 504 | |a Fairchild, C., Ivy, S.P., Kao-Shan, C., Whang-Peng, J., Rosen, N., Israel, M., Melera, P., Goldsmith, M., Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells (1987) Cancer Res, 47, pp. 5141-5148 | ||
| 504 | |a Gottesman, M.M., Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter (1993) Annu Rev Biochem, 62, pp. 385-427 | ||
| 504 | |a Salmon, S., Grogan, T., Miller, T., Scheper, R., Dalton, W., Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining (1989) J Natl Cancer Inst, 81, pp. 696-701 | ||
| 504 | |a Vickers, P.J., Dickson, R.B., Shoemaker, R., Cowan, K.H., A multidrug - Resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo (1988) Mol Endocrinol, 2, pp. 886-892 | ||
| 504 | |a Whelan, R.D., Hill, B.T., Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation (1993) Breast Cancer Res Treat, 26, pp. 23-39 | ||
| 504 | |a Soule, H.D., Vazquez, J., Long, A., Albert, S., Brennan, M., A human cell line from a pleural effusion derived from a breast carcinoma (1973) J Natl Cancer Inst, 51, pp. 1409-1415 | ||
| 504 | |a Bover, L., Barrio, M., Slavutsky, I., Bravo, A.I., Quintans, C., Bagnati, A., Lema, B., Mordoh, J., Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor (1991) Breast Cancer Res Treat, 19, pp. 47-56 | ||
| 504 | |a Bravo, A.I., Sorin, I., Guman, N., Mordoh, J., Carcinoembryonic antigen and differentiation in human breast cancer (1985) J Exp Clin Cancer Res, 4, pp. 3-10 | ||
| 504 | |a Hakomori, S., Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives (1985) Cancer Res, 45, pp. 2405-2414 | ||
| 504 | |a Kim, Y.S., Altered glycosylation of mucin glycoproteins in colonic neoplasia (1992) J Cell Biochem (Suppl), 16 G, pp. 91-96 | ||
| 504 | |a Kim, Y.S., Carbohydrate antigen expression in colorectal cancer (1990) Sem Cancer Biol, 1, pp. 189-197 | ||
| 504 | |a Ho, S.B., Kim, Y.S., Carbohydrate antigens on cancer-associated mucin-like molecules (1991) Sem Cancer Biol, 2, pp. 389-400 | ||
| 504 | |a Urdal, D.L., Brentnall, T.A., Bernstein, I.D., Hakomori, S.I., A granulocyte reactive monoclonal antibody, IG10, identifies the galbl-4 (Fucal-3) GlcNAc (x determinant) expressed in HL60 cells on both glycolipid and glycoprotein molecules (1983) Blood, 62, pp. 1022-1026 | ||
| 504 | |a Singhal, A.K., Orntoft, T.F., Nudelman, E., Nance, S., Schibig, L., Stroud, M.R., Clausen, H., Hakomori, S., Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma (1990) Cancer Res, 50, pp. 1375-1380 | ||
| 504 | |a Zhang, S., Zhang, H.S., Cordon-Cardo, C., Reuter, V.E., Singhal, A.K., Lloyd, K.O., Livingston, P.O., Selection of tumor antigens as targets for immune attack using immunohistochemistry. Blood group-related antigens Int J Cancer, , in press | ||
| 504 | |a D'Arpa, P., Liu, L.F., Topoisomerase-targeting antitumor drugs (1989) Biochim Biophys Acta, 989, pp. 163-177 | ||
| 504 | |a Hudis, C., Seldman, A., Raptis, G., Fennelly, D., Gilewski, T., Baselga, J., Theodoulou, M., Norton, L., Sequential adjuvant therapy: The Memorial Sloan-Kettering Cancer Center experience (1996) Semin Oncol, 23, pp. 58-64 | ||
| 504 | |a Jordan, M.A., Toso, R.J., Thrower, D., Wilson, L., Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations (1993) Proc Natl Acad Sci USA, 90, pp. 9552-9556 | ||
| 520 | 3 | |a Monoclonal antibody (MAb) FC-2.15 recognizes Lewis x antigen (Le(x)-Ag) expressed on the cell surface of most human breast cancer cells. FC-2.15 displays important human complement (C')-mediated cytotoxicity (CMC) against its target cells. In this study the reactivity of FC-2.15 against drug resistant-breast cancer cells was investigated, as well as the possibility to combine the antitumor activities of this MAb with adriamycin (Adr) or taxol. Since resistant clones with altered expression of tumor-associated antigens usually emerge after chemotherapy, the expression of Le(x)-Ag was analyzed in Adr(R) MCF-7 breast cancer cells (Adr resistant subline) and in tumor samples from nine patients with locally advanced breast carcinoma who were treated with FEC chemotherapy. A flow cytometry assay showed that most of Adr(R) MCF-7 cells, as well as wild type (WT) cells, expressed Le(x)-Ag; however, the Le(x) epitope is probably bound to different backbones in these cells. When the cytotoxic ability of FC-2.15 against WT and Adr(R) MCF-7 cells was compared, it was found that a 90 min treatment with FC-2.15 plus C' induced similar CMC against both cell lines. An important cytolysis was obtained at 5 μg/ml FC-2.15, reaching a plateau at 25 μg/ml, at which cell population was diminished to 21.1% for WT and 27.9 for Adr(R) MCF-7 cells. Regarding human tumors, Le(x)-Ag expression was evaluated in samples obtained before and in most cases after chemotherapy, and it could be observed that: 1) before treatment, tumor samples from all patients analyzed (responders and non-responders to chemotherapy) were FC-2.15-positive; 2) the presence of Le(x)-Ag was not modified after treatment. The combined action of Adr or taxol with FC-2.15 was then evaluated. WT and Adr(R) MCF-7 cells were cultured with Adr or taxol followed by an incubation with different FC-2.15 concentrations plus C'. When the effect of Adr alone was determined, ID50 were 1 x 10-7 M for WT and 4.2 x 10-5 M for Adr(R) MCF-7 cells. The cytotoxic ability of taxol alone was also tested, and ID50 were 6.4 x 10-9 M for WT and 3.1 x 10-6 M for Adr(R) MCF-7 cells. When FC-2.15 was added to Adr or taxol, the cytotoxicity of the drug-FC-2.15 combined treatment was always higher than the isolated effects, showing additive cytotoxicity at the different concentrations tested and with both cell lines. Our results suggest that FC-2.15 may be a useful agent against breast tumor cells which survive chemotherapy with Adr or taxol. |l eng | |
| 536 | |a Detalles de la financiación: This work was supported by Grants from the Fun-dación Sales (Argentina), the Fundación para la In-vestigación Prevención del Cancer (FUCA) (Argentina), and the Fundación María Calderón de la Barca (Argentina). JM is a member of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. PP is a Fellow of Funda-ción Sales. | ||
| 593 | |a Fac. de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina | ||
| 593 | |a Inst. Invest. Bioquimicas Fund. C., Buenos Aires, Argentina | ||
| 593 | |a Hospital Rivadavia, Buenos Aires, Argentina | ||
| 593 | |a Inst. Invest. Bioquimicas Fund. C., Patricias Argentinas 435, 1405 Buenes Aires, Argentina | ||
| 690 | 1 | 0 | |a ADRIAMYCIN |
| 690 | 1 | 0 | |a BREAST CANCER |
| 690 | 1 | 0 | |a MDR |
| 690 | 1 | 0 | |a MONOCLONAL ANTIBODY |
| 690 | 1 | 0 | |a TAXOL |
| 690 | 1 | 0 | |a ANTIBODY |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENT |
| 690 | 1 | 0 | |a COMPLEMENT |
| 690 | 1 | 0 | |a CYCLOPHOSPHAMIDE |
| 690 | 1 | 0 | |a DOXORUBICIN |
| 690 | 1 | 0 | |a EPIRUBICIN |
| 690 | 1 | 0 | |a FLUOROURACIL |
| 690 | 1 | 0 | |a MEMBRANE ANTIGEN |
| 690 | 1 | 0 | |a MONOCLONAL ANTIBODY |
| 690 | 1 | 0 | |a PACLITAXEL |
| 690 | 1 | 0 | |a TUMOR ANTIGEN |
| 690 | 1 | 0 | |a ANTIGEN EXPRESSION |
| 690 | 1 | 0 | |a ANTINEOPLASTIC ACTIVITY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BLOOD GROUP LEWIS SYSTEM |
| 690 | 1 | 0 | |a BREAST CANCER |
| 690 | 1 | 0 | |a CANCER CELL |
| 690 | 1 | 0 | |a CANCER CELL CULTURE |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a CYTOLYSIS |
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a FLOW CYTOMETRY |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN CELL |
| 690 | 1 | 0 | |a MOLECULAR RECOGNITION |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a ANTIBODIES, MONOCLONAL |
| 690 | 1 | 0 | |a ANTIGENS, CD15 |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENTS |
| 690 | 1 | 0 | |a BREAST NEOPLASMS |
| 690 | 1 | 0 | |a CELL SURVIVAL |
| 690 | 1 | 0 | |a DOXORUBICIN |
| 690 | 1 | 0 | |a DRUG RESISTANCE, NEOPLASM |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a PACLITAXEL |
| 690 | 1 | 0 | |a TUMOR CELLS, CULTURED |
| 700 | 1 | |a Portela, P. | |
| 700 | 1 | |a Schiaffi, J. | |
| 700 | 1 | |a Yomha, R. | |
| 700 | 1 | |a Mordoh, J. | |
| 773 | 0 | |d 1998 |g v. 47 |h pp. 163-170 |k n. 2 |p Breast Cancer Res. Treat. |x 01676806 |t Breast Cancer Research and Treatment | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031963756&doi=10.1023%2fA%3a1005949118919&partnerID=40&md5=23b66d152199db6e066045e10f810780 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1023/A:1005949118919 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_01676806_v47_n2_p163_Ballare |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01676806_v47_n2_p163_Ballare |y Registro en la Biblioteca Digital |
| 961 | |a paper_01676806_v47_n2_p163_Ballare |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 63942 | ||